Literature DB >> 34914922

SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.

Daniel Wendisch1, Oliver Dietrich2, Tommaso Mari3, Saskia von Stillfried4, Ignacio L Ibarra5, Mirja Mittermaier6, Christin Mache7, Robert Lorenz Chua8, Rainer Knoll9, Sara Timm10, Sophia Brumhard1, Tobias Krammer2, Henrik Zauber3, Anna Luisa Hiller1, Anna Pascual-Reguant11, Ronja Mothes12, Roman David Bülow4, Jessica Schulze7, Alexander M Leipold2, Sonja Djudjaj4, Florian Erhard13, Robert Geffers14, Fabian Pott15, Julia Kazmierski15, Josefine Radke16, Panagiotis Pergantis1, Kevin Baßler9, Claudia Conrad1, Anna C Aschenbrenner17, Birgit Sawitzki18, Markus Landthaler19, Emanuel Wyler19, David Horst20, Stefan Hippenstiel21, Andreas Hocke21, Frank L Heppner22, Alexander Uhrig1, Carmen Garcia1, Felix Machleidt1, Susanne Herold23, Sefer Elezkurtaj20, Charlotte Thibeault1, Martin Witzenrath21, Clément Cochain24, Norbert Suttorp21, Christian Drosten25, Christine Goffinet15, Florian Kurth26, Joachim L Schultze27, Helena Radbruch28, Matthias Ochs29, Roland Eils8, Holger Müller-Redetzky1, Anja E Hauser11, Malte D Luecken5, Fabian J Theis30, Christian Conrad8, Thorsten Wolff7, Peter Boor4, Matthias Selbach31, Antoine-Emmanuel Saliba32, Leif Erik Sander33.   

Abstract

COVID-19-induced "acute respiratory distress syndrome" (ARDS) is associated with prolonged respiratory failure and high mortality, but the mechanistic basis of lung injury remains incompletely understood. Here, we analyze pulmonary immune responses and lung pathology in two cohorts of patients with COVID-19 ARDS using functional single-cell genomics, immunohistology, and electron microscopy. We describe an accumulation of CD163-expressing monocyte-derived macrophages that acquired a profibrotic transcriptional phenotype during COVID-19 ARDS. Gene set enrichment and computational data integration revealed a significant similarity between COVID-19-associated macrophages and profibrotic macrophage populations identified in idiopathic pulmonary fibrosis. COVID-19 ARDS was associated with clinical, radiographic, histopathological, and ultrastructural hallmarks of pulmonary fibrosis. Exposure of human monocytes to SARS-CoV-2, but not influenza A virus or viral RNA analogs, was sufficient to induce a similar profibrotic phenotype in vitro. In conclusion, we demonstrate that SARS-CoV-2 triggers profibrotic macrophage responses and pronounced fibroproliferative ARDS.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  ARDS; COVID-19; IPF; SARS-CoV-2; fibrosis; lung; macrophages; monocytes; proteomics; pulmonary fibrosis; single-cell transcriptomics

Mesh:

Substances:

Year:  2021        PMID: 34914922      PMCID: PMC8626230          DOI: 10.1016/j.cell.2021.11.033

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

Review 1.  SARS-CoV-2 pathogenesis.

Authors:  Mart M Lamers; Bart L Haagmans
Journal:  Nat Rev Microbiol       Date:  2022-03-30       Impact factor: 60.633

Review 2.  Biology of lung macrophages in health and disease.

Authors:  Helena Aegerter; Bart N Lambrecht; Claudia V Jakubzick
Journal:  Immunity       Date:  2022-09-13       Impact factor: 43.474

3.  New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021.

Authors:  Thomas R Martin; Rachel L Zemans; Lorraine B Ware; Eric P Schmidt; David W H Riches; Lisa Bastarache; Carolyn S Calfee; Tushar J Desai; Susanne Herold; Catherine L Hough; Mark R Looney; Michael A Matthay; Nuala Meyer; Samir M Parikh; Troy Stevens; B Taylor Thompson
Journal:  Am J Respir Cell Mol Biol       Date:  2022-09       Impact factor: 7.748

Review 4.  Immune Cells in Subretinal Wound Healing and Fibrosis.

Authors:  Manon Szczepan; María Llorián-Salvador; Mei Chen; Heping Xu
Journal:  Front Cell Neurosci       Date:  2022-06-10       Impact factor: 6.147

Review 5.  The Good and the Bad: Monocytes' and Macrophages' Diverse Functions in Inflammation.

Authors:  Judith Austermann; Johannes Roth; Katarzyna Barczyk-Kahlert
Journal:  Cells       Date:  2022-06-20       Impact factor: 7.666

Review 6.  Immune response in COVID-19: what is next?

Authors:  Qing Li; Ying Wang; Qiang Sun; Jasmin Knopf; Martin Herrmann; Liangyu Lin; Jingting Jiang; Changshun Shao; Peishan Li; Xiaozhou He; Fei Hua; Zubiao Niu; Chaobing Ma; Yichao Zhu; Giuseppe Ippolito; Mauro Piacentini; Jerome Estaquier; Sonia Melino; Felix Daniel Weiss; Emanuele Andreano; Eicke Latz; Joachim L Schultze; Rino Rappuoli; Alberto Mantovani; Tak Wah Mak; Gerry Melino; Yufang Shi
Journal:  Cell Death Differ       Date:  2022-05-17       Impact factor: 12.067

7.  The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19.

Authors:  Christoph Schultheiß; Edith Willscher; Lisa Paschold; Cornelia Gottschick; Bianca Klee; Svenja-Sibylla Henkes; Lidia Bosurgi; Jochen Dutzmann; Daniel Sedding; Thomas Frese; Matthias Girndt; Jessica I Höll; Michael Gekle; Rafael Mikolajczyk; Mascha Binder
Journal:  Cell Rep Med       Date:  2022-06-21

Review 8.  Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Valentina Gallo; Alyexandra Arienzo; Stefano Iacobelli; Valentina Iacobelli; Giovanni Antonini
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 9.  Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review.

Authors:  Areez Shafqat; Shameel Shafqat; Sulaiman Al Salameh; Junaid Kashir; Khaled Alkattan; Ahmed Yaqinuddin
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

10.  Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19.

Authors:  Jan C Kamp; Lavinia Neubert; Maximilian Ackermann; Helge Stark; Christopher Werlein; Jan Fuge; Axel Haverich; Alexandar Tzankov; Konrad Steinestel; Johannes Friemann; Peter Boor; Klaus Junker; Marius M Hoeper; Tobias Welte; Florian Laenger; Mark P Kuehnel; Danny D Jonigk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.